166 related articles for article (PubMed ID: 33302475)
21. Monofunctional platinum(II) complexes with potent tumor cell growth inhibitory activity: the effect of a hydrogen-bond donor/acceptor N-heterocyclic ligand.
Margiotta N; Savino S; Gandin V; Marzano C; Natile G
ChemMedChem; 2014 Jun; 9(6):1161-8. PubMed ID: 24799414
[TBL] [Abstract][Full Text] [Related]
22. Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy.
Czapar AE; Zheng YR; Riddell IA; Shukla S; Awuah SG; Lippard SJ; Steinmetz NF
ACS Nano; 2016 Apr; 10(4):4119-26. PubMed ID: 26982250
[TBL] [Abstract][Full Text] [Related]
23. DNA Intercalation Facilitates Efficient DNA-Targeted Covalent Binding of Phenanthriplatin.
Almaqwashi AA; Zhou W; Naufer MN; Riddell IA; Yilmaz ÖH; Lippard SJ; Williams MC
J Am Chem Soc; 2019 Jan; 141(4):1537-1545. PubMed ID: 30599508
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines.
Song L; Cui Z; Guo X
Acta Biochim Biophys Sin (Shanghai); 2020 Sep; 52(9):944-953. PubMed ID: 32716023
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of disheveled-2 resensitizes cisplatin-resistant lung cancer cells through down-regulating Wnt/β-catenin signaling.
Luo K; Gu X; Liu J; Zeng G; Peng L; Huang H; Jiang M; Yang P; Li M; Yang Y; Wang Y; Peng Q; Zhu L; Zhang K
Exp Cell Res; 2016 Sep; 347(1):105-113. PubMed ID: 27432651
[TBL] [Abstract][Full Text] [Related]
26. Non-classical platinum-based compound 56MESS, with preferential cytotoxic effect on oral cancer cells by downregulating FACL4 expression.
Miao L; Yu P; Huang J; Zhuang Z; Liu X
Pharmazie; 2020 Oct; 75(10):494-499. PubMed ID: 33305724
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
28. Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells.
Bar J; Hasim MS; Baghai T; Niknejad N; Perkins TJ; Stewart DJ; Sekhon HS; Villeneuve PJ; Dimitroulakos J
Neoplasia; 2016 Sep; 18(9):525-35. PubMed ID: 27659012
[TBL] [Abstract][Full Text] [Related]
29. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
30. Versatile Pt NCs-based chemotherapeutic agents significantly induce the apoptosis of cisplatin-resistant non-small cell lung cancer.
Xin Y; Huang X; Li Z; Zhao W; Wang C; Wang S; Yue X; Mo H; Li H
Biochem Biophys Res Commun; 2019 Apr; 512(2):218-223. PubMed ID: 30885437
[TBL] [Abstract][Full Text] [Related]
31. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
32. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
33. A monofunctional platinum(II)-based anticancer agent from a salicylanilide derivative: Synthesis, antiproliferative activity, and transcription inhibition.
Wang B; Wang Z; Ai F; Tang WK; Zhu G
J Inorg Biochem; 2015 Jan; 142():118-25. PubMed ID: 25450026
[TBL] [Abstract][Full Text] [Related]
34. Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment.
He L; Wang X; Liu K; Wu X; Yang X; Song G; Zhang B; Zhong L
Gene; 2019 Apr; 691():70-76. PubMed ID: 30584903
[TBL] [Abstract][Full Text] [Related]
35. Fresh platinum complexes with promising antitumor activity.
Wang X
Anticancer Agents Med Chem; 2010 Jun; 10(5):396-411. PubMed ID: 20545618
[TBL] [Abstract][Full Text] [Related]
36. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
37. Effects of dinuclear berenil-platinum(II) complexes on fibroblasts redox status.
Gęgotek A; Markowska A; Łuczaj W; Bielawska A; Bielawski K; Ambrożewicz E; Skrzydlewska E
Adv Med Sci; 2013; 58(2):282-91. PubMed ID: 24127544
[TBL] [Abstract][Full Text] [Related]
38. Gold(III) compounds-mediated inhibition of lung cancer cell proliferation.
Bostancioğlu RB; Kaya M; Koparal AT; Benkli K
Anticancer Drugs; 2016 Mar; 27(3):225-34. PubMed ID: 26825752
[TBL] [Abstract][Full Text] [Related]
39. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
40. A monofunctional trinuclear platinum complex with steric hindrance demonstrates strong cytotoxicity against tumor cells.
Wu S; Wang X; He Y; Zhu Z; Zhu C; Guo Z
J Inorg Biochem; 2014 Oct; 139():77-84. PubMed ID: 24991692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
